These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2808213)

  • 1. Meropenem: evidence of lack of proconvulsive tendency in mice.
    Patel JB; Giles RE
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():307-9. PubMed ID: 2808213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
    Day IP; Goudie J; Nishiki K; Williams PD
    Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
    Jin C; Jung I; Ku HJ; Yook J; Kim DH; Kim M; Cho JH; Oh CH
    Toxicology; 1999 Nov; 138(2):59-67. PubMed ID: 10576583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
    Yousif T; Pooyeh S; Hannemann J; Baumann J; Tauber R; Baumann K
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of seizures among the carbapenems: a meta-analysis.
    Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
    J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicity of carbapenem antibacterials.
    Norrby SR
    Drug Saf; 1996 Aug; 15(2):87-90. PubMed ID: 8884160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of carbapenem and penem compounds for the convulsive property.
    Sunagawa M; Matsumura H; Fukasawa M
    J Antibiot (Tokyo); 1992 Dec; 45(12):1983-5. PubMed ID: 1490893
    [No Abstract]   [Full Text] [Related]  

  • 8. Imipenem but not meropenem induces convulsions in DBA/2 mice, unrelated to cerebrospinal fluid concentrations.
    Dupuis A; Pariat C; Courtois P; Couet W; Bouquet S
    Fundam Clin Pharmacol; 2000; 14(2):163-5. PubMed ID: 10796065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of meropenem in animals: studies on the kidney.
    Topham JC; Murgatroyd LB; Jones DV; Goonetilleke UR; Wright J
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():287-306. PubMed ID: 2681127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain.
    Sunagawa M; Matsumura H; Sumita Y; Nouda H
    J Antibiot (Tokyo); 1995 May; 48(5):408-16. PubMed ID: 7797443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice.
    de Sarro A; Imperatore C; Mastroeni P; de Sarro G
    J Pharm Pharmacol; 1995 Apr; 47(4):292-6. PubMed ID: 7791026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal model for evaluating the convulsive liability of beta-lactam antibiotics.
    Williams PD; Bennett DB; Comereski CR
    Antimicrob Agents Chemother; 1988 May; 32(5):758-60. PubMed ID: 3395104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
    Horiuchi M; Kimura M; Tokumura M; Hasebe N; Arai T; Abe K
    Toxicology; 2006 May; 222(1-2):114-24. PubMed ID: 16549226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR
    Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
    Wu Y; Chen K; Shi Z; Wang Q
    Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A carbapenem antibiotic imipenem/cilastatin induces an oxidative stress-status and gonadotoxic effects in « wistar » rats.
    Tahri A; Ksouda K; Kallel R; Daoud S; Boudawara T; Zeghal KM; Sahnoun Z
    Biomed Pharmacother; 2017 Nov; 95():308-316. PubMed ID: 28858728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.